



Testing the genomic medicine paradigm in practice

The Clalit 100K Israeli Genomes RCT

Gad Rennert, M.D., Ph.D.

Clalit National Personalized medicine program
Clalit National Cancer Control Center (NICCC)
Carmel Medical Center, Technion Faculty of Medicine,
Haifa, Israel

OVERALL AIM

To evaluate **clinical** and **economic** outcomes of implementing a comprehensive genomic medicine approach into usual primary care clinical service.

Comparison of outcome between intervention and control clinics.

Randomized Controlled Study

Cluster Randomization by Clinic type
40 primary care clinics
in Clalit's Haifa/WG District

- 20 intervention clinics
- 20 matches usual care clinics


Largest Health Care

Provider in Israel



"Secondary" outcome

- Genomic atlas of Israeli populations (Jewish, Moslem, Christian, Druze, Bedouin)
- Identification of gene-disease associations (all genes vs. all diseases, all treatments)



Five Study phases

OUTCOMES ANALYSIS

CLINICAL ACTION-

Delivery of actionable results

BIOINFORMATICS

GENETIC TESTING

WES/WGS + 750K SNPs array

PRIMARY CARE CLINIC TEAM


Attitudes, genetics course, scenario practice

POPULATION

Attitudes, agreement to test, education, sample collection

Current Status - breaking ground

- Clinics randomized
- Population phase
 - 2 focus groups X 3 clinics, to identify barriers
 - While discussing barriers and worries ALL participants agreed to give blood (selection?)
 - Preparing questionnaire to total target population
- Clinic phase
 - Introductory meeting with clinic leaders (chief physician, nurse and pharmacist) of 3 first clinics
- May 2018: National Genetic IRB approved consent form (process started in 2016)
- 2019 Launched: 1st Clinic, 1500 joined
- 2020 COVID19 : full stop



Thank you from HAIFA

